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Aim. To study the association of polymorphisms of the enzymes genes CYP1A1 (T6235C), first phase, and
NAT2 (Ñ481Ò, G590A, G857A), GSTM1 («0»), GSTT1 («0») and GSTP1 (A313G), second phase of the
detoxication system, as well as the ADRB2 (C79G) gene variants with the development of bronchial asthma
in children. Methods. Polymorphic variants were analyzed using PCR followed by RFLP analysis in 86
healthy individuals and in 114 patients with clinical diagnosis of bronchial asthma. Results. The frequency
of gene polymorphic variants of the enzymes of first and second phases of detoxification system as well as
the ADRB2 gene was established in the children with bronchial asthma and healthy individuals.
Conclusions. Ðolymorphic variants of the genes NAT2 (481Ò), GSTP1 (313G) and ADRB2 (79G) and their
combinations in geno- type were observed more frequently in the patients with bronchial asthma comparing
to the control group, which indicates their invol- vement in the pathogenesis of asthma in children
Keywords: bronchial asthma, detoxication system, 2-adrenoreceptor gene, polymorphism, combined
genotype.
Introduction. Bronchial asthma (BA), a chronic
inflammation of respiratory tracts, is an urgent medical
and social problem in Ukraine and around the world,
which is remarkable for high incidence and lethality as
well as considerable economic cost, related to
disability of patients with BA [1–5]. Recent
epidemiologic research has demonstrated that 4–35%
of population in different countries, including 5–10%
of children, suffer from BA [4–8]. During recent 10–15
years the increase in environmental pollution and
appearance of new chemical allergens raised the
number of patients with BA, while their treatment is
not always efficient, besides, the patients often have
adverse drug reaction [1, 6].
Up-to-date it has been established that BA is a
complex disorder, etiology and pathogenesis of which
are determined by complicated interaction of genetic
and environmental factors [8–10]. The research of
molecular and genetic grounds of hereditary
predisposition to BA is mainly concentrated on
determination of the role of certain genes and enzymes,
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coded by them, in BA pathogenesis as well as in the
efficiency of therapy of this disease.
It was determined that due to anatomic and
physiological specificities of childhood (narrow
bronchial lumen, increased vascularity of respiratory
tracts, insufficient rigidity of thoracic cage and
elasticity of lungs, weak development of unstriated
bronchial muscles, hypersecretion of viscous mucus by
goblet cells) BA in children is accompanied by
prevalence of edema of mucous membrane and mucus
discharge into bronchial lumen over spasm of
unstriated muscles [11]. The same work states that
bronchial spasm in older children, like in adults, is
more frequent than edema of mucous membrane.
Bronchial hyperreactivity changes with age – it is more
expressed in children and old people than in
middle-aged people. However, BA may be without
bronchial hyperreactivity. Assumed triggers of
bronchoconstriction are considered to be viral
infections, physical activity, and external chemical
pollutants. Contrary to adults, children suffer from
viral infections most frequently [11].
The genes of detoxication system enzymes are
considered as possible markers of hereditary
predisposition to atopy and associated diseases because
their protein products participate in the metabolism of
mediators of allergic inflammation as well as in the
regulation of mechanisms of oxidative stress, playing
an important role in BA pathogenesis in children [10,
12–17].
The specificity of enzymes of P450 cytochrome
system is their high activity in main ways of
xenobiotics influx into an organism, namely
respiratory and food pathes.
It was also revealed that glutathione-S-transferase
(GSTM1, GSTT1 and GSTP1) are involved into
intracellular transport of hormones and biosynthesis of
prostaglandins. Especially high concentrations of these
enzymes are observed in lungs, liver, kidneys, and
gastrointestinal tract [18–22]. Long deletion was
described for GSTM1 and GSTT1 genes, due to which
RNA and protein product are not synthesized at all (so
called “0” allele). It was determined that in majority of
populations and ethnic groups the number of
individuals, homozygous by this allele, is 35–50%
[17]. It was also shown that genetic polymorphism,
determined by single nucleotide polymorphism A313G
in GSTP1 gene, results in the production of less active
enzyme form [8, 17]. A protein product of GSTP1 gene
was found in different organs, including lungs [8, 17].
N-acetyltransferases provide for acetylation of
many xenobiotics, especially drugs, containing
aromatic amine or hydrazine groups. Toxic
nitrosamines in tobacco smoke and pesticides also
belong to NAT2 substrates. Molecular basis for the
existence of “fast” and “slow acetylizers” is considered
to be NAT2 gene polymorphisms [17].
2-adrenoreceptors are localized in bronchi,
vessels of most organs as well as almost in all cells,
participating in immune response. Their activation
causes bronchoectasia which indicates an important
role of adrenoreceptors in normal functioning of the
respiratory system. Individuals with observed
decreased activity of 2-receptors have a higher risk of
developing the clinical picture of BA via
bronchoconstriction. Another considerable evidence to
the association of polymorphisms in 2-adreno-
receptor gene with BA pathogenesis is the data on high
efficiency of BA therapy in children using stimulation
with 2-agonists [13–15]. The study on efficiency of
inhalational therapy with â-agonists in patients with
asthma revealed dependence between bronchodilation
and definite mononucleotide polymorphisms of
ADRB2 gene [12].
Taking these data into consideration, the aim of our
work was to study the association of
polymorfalCYP1A1 (T6235C) first phase and second
NAT2 (C481T, G590A, G857A), GSTM1 («0»),
GSTT1 («0») and GSTP1 (A313G) phase detoxication
system enzymes genes polymorphisms, and also
ADRB2 (C79G) gene variants, with the development of
bronchial asthma in children.
Materials and Methods. Three groups of
individuals were analyzed. Two groups of children
with BA were presented by unrelated individuals from
two regions of Ukraine: Kyiv and Kyiv Region
(observation group I) and Dniprodzerzhynsk,
Dnipropetrovsk Region (observation group II). In
accordance to the analytical report “Ukrainian
Environment in 2009”, posted at web-site of the State
Statistics Committee of Ukraine, Dniprodzerzhynsk
takes the 8
th place among Ukrainian cities in
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anthropogenic load from stationary pollution sources
with 110.8 thousand tons of emissions of harmful
substances [23]. The ecological state of Kyiv and Kyiv
Region is considerably better. The groups were formed
in 2008 and 2009. Informed consent forms for
participation in the research were signed by parents of
each participant. This research was approved by the
Bioethics Committees of the Institute of Molecular
Biology and Genetics, NAS of Ukraine, and State
Enterprise “Institute of Pediatrics, Obstetrics, and
Gynecology”, NAMS of Ukraine.
The observation group I consisted of 52 patients,
including 32 (61.5%) male and 20 (38.5%) female
individuals. The observation group II consisted of 62
patients, including 43 (69.4 %) male and 19 (30.6 %)
female individuals. Totally these two groups with
clinical diagnosis of BA comprised 114 patients, 75
(65.8%) male and 39(34.2%) female individuals, aged
from 3 to 18 years old. During several years patients
from both investigated groups had defined diagnosis of
BA and prior to the research they passed unified
medical examination in accordance with the
recommendations of the Ministry of Health of Ukraine
and Global Initiative for Asthma. The results of clinical
research and observed symptoms indicate persisting
BA of medium degree at the stage of clinical remission
in all sick children. The control group comprised 86
unrelated healthy adults from different regions of
Ukraine (oocyte donors, their health condition and BA
absence in anamnesis were confirmed by the results of
medical examination). This group may be considered
representative for estimation of DNA polymorphism
frequency in autosomal genes [24, 25].
Genotyping. DNA was isolated from leukocytes of
peripheral blood by standard method [26].
Polymorphic variants of genes CYP1A1 (T6235C)
[27], GSTP (A313G) [28], NAT2 (Ñ481Ò, G590A and
G857A) [29], and homozygotes by deletions inGSTM1
and GSTT1 genes [29], as well as ADRB2 (C79G)
variants [30] were detected as described in
corresponding works.
The data were statistically processed using MDR
and OpenEpi software and Fisher’s test, as well as odd
ratio (OR) calculation [31, 32].
Results and Discussion. The results of molecular
and genetic analysis of the polymorphic variants of the
enzyme genes of first -CYP1A1 (T6235C), and second
- NAT2 (C481T, G590A, G857A), GSTM1 («0»),
GSTT1 («0») and GSTP1 (A313G) phases of the
detoxication system as well as ADRB2 (C79G) gene
polymorphism in the observation groups I and II, and in
the control group allowed obtaining the distribution of
revealed genotypes and allele variants. The data are
presented in Table 1.
It is noteworthy that there was no statistically
reliable difference in the frequency of genotypes with
GSTM1, GSTT1 and CYP1A1 gene polymorphisms
between the observation groups I, II and the control
group. The data on the absence of any association
between homozygous deletions of GSTM1 and GSTT1
genes and the development of hereditary predisposition
to the occurrence of bronchopulmonary pathologies
(chronic obstructive lung disease) were received in the
work of Gorovenko et al. [7]. On the other hand, in a
number of works the authors revealed association of
these polymorphisms and the risk of BA development
in children [17] and in adults [10]. Besides, the
research, performed in Ukraine [5], revealed the
relation of homozygous deletion of GSTT1 gene to the
development of hereditary predisposition to BA in
adults, while there was no determined association of
homozygous deletion of GSTM1 gene with the BA
development in adults. These conflicting results testify
to the necessity of extending the research and control
groups, involved in the experiment. It is noteworthy
that the data obtained by us regarding the absence of
association of CYP1A1 gene polymorphism, are in
good agreement with the results obtained for other
gene polymorphisms of P-450 family (CYP2C19 and
CYP2E1) [10].
It was determined that total frequency of hetero-
and homozygous carriers of polymorphic allele 313G
of GSTP1 gene is reliably higher (P < 0.05) in both the
observation group I (51.9%) and group II (56.5%)
compared to the control group (33.7%). The same
regularity was observed for the frequency of this allele
in the corresponding groups. The results of OR indices
calculation show that the risk of BA development in
children is 2.5-fold increased for both hetero- and
homozygous carriers of polymorphic allele 313G
GSTP1 gene (OR = 2.548, CI – 95%: 1.3–4.93).A
number of investigations revealed that this enzyme was
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Gene
Control group, n
= 86
Observation
group ²,
n = 52
Observation
group ²²,
n = 62
Gene
Control group, n
= 86
ÃObservation
group ²,
n = 52
Observation
group ²²,
n = 62
CYP1A1 (T6235C) NAT2 (C481T)
Genotype, n (%) Allele, n (frequency)
TT 72 (83,6) 44 (84,6) 46 (74,2) F (C) 90 (0,558) 53 (0,509) 75 (0,605)
TC 12 (14) 8 (15,4) 14 (22,6) *5 (T) 76 (0,442) 51 (0,491) 49 (0,395)
CC 2 (2,4) 0 (0) 2 (3,2) NAT2 (G590A)
Allele, n (frequency) Genotype, n (%)
T 156 (0,907) 96 (0,923) 106 (0,855) F/F (GG) 34 (39,5) 26 (50,0) 24 (38,7)
C 16 (0,093) 8 (0,077) 18 (0,145) F/*6 (GA) 46 (53,5) 23 (44,2) 34 (52,8)
GSTP1 (A313G) *6/*6 (AA) 6 (7,0) 3 (5,8) 4 (6,5)
Ãåíîòèï, n (%) Allele, n (frequency)
AA 57 (66,3) 25 (48,1) 27 (43,5) (G) 114 (0,663) 75 (0,721) 82 (0,661)
AG 24 (27,9) 22 (42,3) 32 (51,6) *6 (A) 58 (0,337) 29 (0,279) 42 (0,339)
GG 5 (5,8) 5 (9,6) 3 (4,9) FNAT2 (G857A)
AG + GG 29 (33,7) 27 (51,9)* 35 (56,5)* Genotype, n (%)
Allele, n (frequency) F/F (GG) 79 (91,9) 46 (88,5) 60 (96,8)
A 138 (0,802) 72 (0,692) 86 (0,694) F/*7 (GA) 7 (8,1) 6 (11,5) 2 (3,2)
G 34 (0,198) 32 (0,308)* 38 (0,306)* *7/*7 (AA) 0 (0) 0 (0) 0 (0)
GSTM1 («0») Allele, n (frequency)
Genotype, n (%) F (G) 165 (0,959) 98 (0,942) 122 (0,984)
+/+ i +/«0» 39 (45,3) 28 (53,8) 32 (51,6) *7 (A) 7 (0,041) 6 (0,058) 2 (0,016)
«0»/«0» 47 (54,7) 24 (46,2) 30 (48,4) ADRB2 (C79G)
GSTT1 («0») Genotype, n (%)
Genotype, n (%) CC 38 (44,2) 21 (40,4) 19 (30,6)
+/+ i +/«0» 39 (45,3) 28 (53,8) 32 (51,6) CG 36 (41,9) 20 (38,5) 36 (58,1)
«0»/«0» 47 (54,7) 24 (46,2) 30 (48,4) GG 12 (13,9) 11 (21,1) 7 (11,3)
NAT2 (C481T) CG + GG 48 (55,8) 31 (59,6) 43 (69,4)*
Genotype, n (%) Allele, n (frequency)
F/F (CC) 20 (23,3) 14 (26,9) 23 (37,1) C 112 (0,651) 62 (0,596) 74 (0,597)
F/*5 (CT) 56 (65,1) 25 (48,1) 29 (46,8) G 60 (0,349) 42 (0,404) 50 (0,403)
*5/*5 (TT) 10 (11,6) 13 (25,0)* 10 (16,1)
Table 1
Distribution of genotypes and allele variants in investigated groups
Note. N – number of individuals; *statistically reliable difference (P < 0,05); CYP1A1: T – 6235T, C – 6235C; NAT2: F (C) – 481C, *5 (T) –
481T, F (G) – 590G, *6 (A) – 590A, F (G) – 857G, *7 (A) – 857A; GSTM1: «0» (deletion) – «0»/«0», + (íîðìà) – +/+ ³ «0»/+; GSTT1: «0»
(deletion) – «0»/«0», + (norm) – +/+ ³ «0»/+; GSTP1: A – 313A, G – 313G; ADRB2: C – 79C, G – 79G.
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Genotype
Control group,
n = 86
Observation group ²,
n = 52
Observation group ²²,
n = 62
NAT2*5 GSTP1 ADRB2 n % n % n %
1 CC AA CC 3 3,5 3 5,8 2 3,2
2 CT AA CC 19 22,1 5 9,6 4 6,5
3 CC AA CG 7 8,1 3 5,8 4 6,5
4 CC AA GG 3 3,5 2 3,8 1 1,6
5 CC AG CC 1 1,2 1 1,9 8 12,9
6 CC AG CG 3 3,5 3 5,8 4 6,5
7 CC AG GG 2 2,3 1 1,9 2 3,2
8 ÑÑ GG CC 0 0 0 0 2 3,2
9 CC GG CG 0 0 1 1,9 0 0
10 CC GG GG 1 1,2 0 0 0 0
11 CT AA CG 16 18,6 4 7,7 10 16,1
12 CT AA GG 2 2,3 1 1,9 1 1,6
13 CT AG CC 7 8,1 6 11,5 2 3,2
14 CT AG CG 6 7 2 3,8 9 14,5
15 CT AG GG 3 3,5 4 7,7 2 3,2
16 CT GG CC 2 2,3 1 1,9 0 0
17 CT GG CG 1 1,2 1 1,9 1 1,6
18 CT GG GG 0 0 1 1,9 0 0
19 TT AA CC 3 3,5 2 3,8 0 0
20 TT AA CG 3 3,5 4 7,7 5 8,1
21 TT AA GG 1 1,2 1 1,9 0 0
22 TT AG CC 2 2,3 2 3,8 1 1,6
23 TT AG CG 0 0 2 3,8 3 4,8
24 TT AG GG 0 0 1 1,9 1 1,6
25 TT GG CC 1 1,2 1 1,9 0 0
26 TT GG CG 0 0 0 0 0 0
27 TT GG GG 0 0 0 0 0 0
28 TT/AG + GG/CG + GG 64 74,4 44 84,6 56* 90,3
29 CC + CT/AA/CC 22 25,6 8 15,4 6
9,7
Note. N – number of individuals; *statistically reliable difference (P < 0,05); NAT2: C – 481C, *5 (T) – 481T; GSTP1: A – 313A, G – 313G;
ADRB2: C – 79C, G – 79G.
Table2
Distribution of genotypes and allele variants of GSTP1, NAT2, and ADRB2 genes in investigated groups
expressed in lungs and alveoli [8, 17]. It is also found
that there are several remarkable characteristics of the
enzyme GSTP1 which distinguish it among other
enzymes of the GST family. One of them is the absence
of spatial structure, covering the catalytic centre, which
makes it easily available for substrates. Another
characteristic feature of this enzyme is a double nature
of H-site – it is semi-hydrophobic and semi-
hydrophilic [33]. The existent information allows us to
assume that concentration of this enzyme in lungs is
high, partly because the latter, among other organs of
respiratory system, is on the border of internal and
external media of the organism. So they are the first to
be exposed to the harmful influence of air pollutants.
Therefore, our results and literature data suggest
that the increase in frequency of carriers of poly-
morphic variant 313G ofGST1 gene correlates with the
decrease in the activity of the enzyme in patients with
this genotype, due to which the level of free radicals
increases as well. The latter leads to the increase in the
risk of oxidative stress occurrence in the cells of
bronchopulmonary system. In its turn, it is a probable
prerequisite of BA pathogenesis in children [34].
It was shown that the frequency of homozygous
carriers of polymorphic allele 481T of NAT2 gene is
significantly higher (P < 0.05) in the observation group
I (25%) compared to the control group (11.6%). The
tendency of increasing frequency of individuals with
this genotype was observed in the observation group II
(16.1%).
The enzyme, coded by NAT2 gene, is expressed in
liver and epithelium of intestines [10]. Our study and
the works of other authors demonstrated that about
50% Caucasians belong to so called “slow acetylizers”
S1 (NAT2*5) and S2 (NAT2*6) [8–10, 17]. It is due to
the single nucleotide polymorphisms C481T and
G590A. On the other hand, allele S3 G857A (NAT2*7)
is the most frequent among Mongoloid representatives
[27].
The results of biochemical investigations
demonstrated that the activity of NAT enzymes in all
“slow acetylizers” was decreased by 20% on average in
comparison with the norm (“fast acetylizers”) [17].
Therefore, similar to 313G polymorphism of GST1
gene, less functionally active enzyme forms of NAT2
gene may cause the increase in oxidative stress which is
one of BA agents in children [34]. The obtained results
and the data of other investigators testify to the fact that
“slow” acetylation is a factor of increased risk of BA
development in children [8–10, 18, 19].
While studying allele polymorphism of ADRB2
gene, it was shown that total frequency of hetero- and
homozygous carriers of its polymorphism 79G is
significantly higher (P < 0.05) in the observation group
II (69.4%) compared to the control group (55.8%). The
tendency of increasing frequency of these genotypes
was also observed in the observation group I (59.6%).
It was shown in some works that 2-adrenoreceptors
play an important role in bronchial dilatation and
participate in anti-inflammatory reactions [16].
The investigated polymorphism Gln>Glu (C79G)
in the codon 27 of ADRB2-gene was shown to cause
changing in spatial structure of of the receptor
extracellular domain, which results in the decrease in
its functional ability.
Taking into account that 2-adrenoreceptors are
localized practically in all cells of the immune
response, individuals with these polymorphic alleles
are likely to be more sensitive to allergens and, as a
result, to the development of allergy and inflammations
of different kinds. This conclusion is supported by the
presented data on the increase in the frequency of
carriers of polymorphism 79G of ADRB2 gene in the
group of patients who live in anthropogenically
polluted Dniprodzerzhynsk compared to the control
group and the group of patients from Kyiv.
To analyze a possible cumulative effect of poly-
morphisms 313G, 481T and 79G of GSTP1, NAT2, and
ADRB2 genes, the frequency of which is significantly
higher in the groups of children with BA, individuals
with genotypes, containing these polymorphisms, were
studied. The results of analysis of distribution of these
genotypes in the observation groups and in the control
group are presented in Table 2.
The frequency of individuals with genotypes,
containing polymorphisms 313G, 481T and 79G of
GST1, NAT2, ADRB2 genes and their combinations,
appeared to be significantly higher (P < 0.05,
OR = 3.28, CI – 95%: 1.215–8.747) in the observation
group II (90.3%) compared to the control group
(74.4%). The same tendency was also observed in the
observation group I (84.6%).
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The data obtained suggest that due to the decrease
in the activity of enzymes GSTP1 and NAT2 [8, 17,
33, 34] there may be morphofunctional changes in the
tissues of bronchopulmonary system, caused by
oxidative stress, which is conditioned by the excess of
active forms of oxygen and free radicals. The carriers
of polymorphism 79G of ADRB2 gene may also have
such pathological constituents of BA in children as
modulated immune response and hypertonus of
bronchopulmonary tissues [16, 33, 34].
Therefore, it may be proposed that polymorphisms
313G, 481T, and 79G of GSTP1, NAT2, ADRB2 genes
and their combinations in the genotype are the factors
of increased risk of BA development in children.
The limiting trait of the present study is the absence
of an additional control group consisting of healthy
children who correspond to the observation groups by
their age and gender. Our further investigations will be
aimed at the comparative molecular and genetic study
on the polymorphisms in children with BA and
abovementioned control group for in-depth analysis of
the regularities observed.
Investigation of allele variants and their
combinations related to the increased risk of BA
development in children with the consideration of
environmental factors and family anamnesis will allow
revealing individuals with high risk of BA
development.
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Ðåçþìå
Ìåòà. Äîñë³äèòè çâ’ÿçîê ïîë³ìîðôíèõ âàð³àíò³â ãåí³â ôåð-
ìåíò³â ïåðøî¿ – CYP1A1 (T6235C) òà äðóãî¿ – NAT2 (Ñ481Ò,
G590A, G857A), GSTM1 («0»), GSTT1 («0») ³ GSTP1 (A313G) ôàç
ñèñòåìè äåòîêñèêàö³¿, à òàêîæ ãåíà ADRB2 (C79G) ç ðîçâèò-
êîì áðîíõ³àëüíî¿ àñòìè (ÁÀ) ó ä³òåé. Ìåòîäè. Ïî- ë³ìîðôí³
âàð³àíòè âèâ÷àëè çà äîïîìîãîþ ÏËÐ òà ÏÄÐÔ-àíàë³çó ó 86
çäîðîâèõ ³íäèâ³ä³â òà ó 114 ïà- ö³ºíò³â ç êë³í³÷íèì ä³àãíîçîì
ÁÀ. Ðåçóëüòàòè. Âñòàíîâëåíî ÷àñòîòó ïîë³ìîðôíèõ
âàð³àíò³â ãåí³â ôåðìåíò³â ïåðøî¿ ³ äðóãî¿ ôàç ñèñòåìè äåòîê-
ñèêàö³¿, à òàêîæ ãåíà ADRB2 ó õâîðèõ íà ÁÀ ä³òåé òà ó çäîðî-
âèõ ³íäèâ³ä³â. Âèñíîâêè. Ïîë³ìîðôí³ âàð³àíòè ãåí³â NAT2
(481Ò), GSTP1 (313G) ³ ADRB2 (79G) òà ¿õí³ êîìá³íàö³¿ â ãåíî-
òèï³ ÷àñò³øå ñïîñòåð³ãàþòüñÿ ñåðåä ïàö³ºíò³â ç ÁÀ ïîð³âíÿíî
ç êîíò- ðîëüíîþ ãðóïîþ, ùî ñâ³ä÷èòü íà êîðèñòü çàëó÷åííÿ ¿õ
äî ïàòîãåíåçó ÁÀ ó ä³òåé.
Êëþ÷îâ³ ñëîâà: áðîíõ³àëüíà àñòìà, ñèñòåìà äåòîêñèêàö³¿, ãåí
2-àäðåíîðåöåïòîðà, ïîë³ìîðô³çì, êîìá³íîâàíèé ãåíîòèï.
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Ï. Ô. Òàòàðñêèé, Í. Ã. ×óìà÷åíêî, À. Ì. Êó÷åðåíêî,
Ð. Â. Ãóëêîâñêèé, Ë. Ï. Àðàáñêàÿ, Î. À. Ñìèðíîâà,
Ñ. È. Òîëêà÷, Þ. Ã. Àíòèïêèí, Ë. À. Ëèâøèö
Èññëåäîâàíèÿ âîçìîæíîé ðîëè ïîëèìîðôèçìà ãåíîâ
CYP1A1, GSTT1, GSTM1, GSTP1, NAT2 è ADRB2
â ðàçâèòèè áðîíõèàëüíîé àñòìû ó äåòåé
Ðåçþìå
Öåëü. Èññëåäîâàòü àññîöèàöèþ ïîëèìîðôíûõ âàðèàíòîâ ãåíîâ
ôåðìåíòîâ ïåðâîé – CYP1A1 (T6235C) è âòîðîé – NAT2
(Ñ481Ò, G590A, G857A), GSTM1 («0»), GSTT1 («0») è GSTP1
(A313G) ôàç ñèñòåìû äåòîêñèêàöèè, à òàêæå ãåíà ADRB2
(C79G) ñ ðàçâèòèåì áðîíõèàëüíîé àñòìû (ÁÀ) ó äåòåé. Ìåòî-
äû. Ïîëèìîðôíûå âàðèàíòû èçó÷àëè ñ ïîìîùüþ ÏÖÐ è ÏÄÐÔ-
àíàëèçà ó 86 çäîðîâûõ èíäèâèäîâ è 114 ïàöèåíòîâ ñ êëèíè÷åñ-
êèì äèàãíîçîì ÁÀ. Ðåçóëüòàòû. Óñòàíîâëåíà ÷àñòîòà ïîëè-
ìîðôíûõ âàðèàíòîâ ãåíîâ ôåðìåíòîâ ïåðâîé è âòîðîé ôàç
ñèñòåìû äåòîêñèêàöèè, à òàêæå ãåíà ADRB2 ó áîëüíûõ ÁÀ äå-
òåé è çäîðîâûõ èíäèâèäîâ. Âûâîäû. Ïîëèìîðôíûå âàðèàíòû
ãåíîâ NAT2 (481Ò), GSTP1 (313G) è ADRB2 79G è èõ êîìáèíà-
öèè â ãåíîòèïå ÷àùå íàáëþäàþòñÿ ñðåäè ïàöèåíòîâ ñ ÁÀ ïî
ñðàâíåíèþ ñ êîíòðîëüíîé ãðóïïîé, ÷òî ñâèäåòåëüñòâóåò â ïî-
ëüçó èõ âîâëå÷åíèÿ â ïàòîãåíåç ÁÀ ó äåòåé.
Êëþ÷åâûå ñëîâà: áðîíõèàëüíàÿ àñòìà, ñèñòåìà äåòîêñèêà-
öèè, ãåí 2-àäðåíîðåöåïòîðà, ïîëèìîðôèçì, êîìáèíèðîâàííûé
ãåíîòèï.
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